NEW YORK, June 27 - Short interfering RNA therapeutics firm Alnylam will likely have products in the clinic within two to three years, CEO John Maraganore said in an interview at the BIO 2003 meeting in Washington, D.C. this week.


To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.